Ipca Laboratories Ltd

Ipca Laboratories Earnings Call Transcript: Key Takeaways

Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.

Ipca Laboratories Q2 FY27 Results: Net Profit ₹389.3 Cr, Up 38.8% YoY

Ipca Laboratories Ltd reported revenue from operations of ₹2,910 Cr (+13.8% YoY) and net profit of ₹389.3 Cr (+38.8% YoY) for Q2 FY27.

Key figure

Net profit ₹389.3 Cr · +38.8% YoY

Ipca Laboratories Board Meeting Date

Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.

Ipca Laboratories Other Announcement

Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.

Ipca Laboratories Earnings Call Transcript: Key Takeaways

Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.

Call

Guides 16% growth

Ipca Laboratories Annual General Meeting

Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.

Ipca Laboratories Q1 FY27 Results: Net Profit ₹424.3 Cr, Up 82.2% YoY

Ipca Laboratories Ltd reported revenue from operations of ₹2,788 Cr (+20.8% YoY) and net profit of ₹424.3 Cr (+82.2% YoY) for Q1 FY27.

Key figure

Net profit ₹424.3 Cr · +82.2% YoY